TCMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
TACTILE SYSTEMS TECHNOLOGY INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$22.73+0.21 (+0.93%)
Close on Oct 19, 2026
- Market cap
- $524.13M
- P/E (TTM)
- 21.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
96.7%
22M of 23M shares
Institutional holders
181
29 new, 30 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 12 sales
Net sold $2.02M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 1,818,693 | 7.70% | 13G (passive) amendment | Mar 31, 2025 |
| Eric Bannasch | 1,576,940 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TCMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,905,086 | 8.41% | $56.73M | +125,640 | 0.00% |
| Cadian Capital Management, LP | 1,576,940 | 6.96% | $46.96M | +535,868 | 3.55% |
| Dimensional Fund Advisors LP | 1,092,193 | 4.82% | $32.53M | +12,477 | 0.01% |
| Morgan Stanley | 979,340 | 4.32% | $29.16M | −403,472 | 0.00% |
| Vanguard Capital Management LLC | 970,246 | 4.28% | $28.89M | +25,149 | 0.00% |
| Driehaus Capital Management LLC | 937,783 | 4.14% | $27.93M | +195,869 | 0.16% |
| Acadian Asset Management LLC | 903,553 | 3.99% | $26.90K | −1,816 | 0.03% |
| Vanguard Portfolio Management LLC | 706,509 | 3.12% | $21.04M | +38,175 | 0.00% |
| Federated Hermes, Inc. | 681,153 | 3.01% | $20.28M | +20,196 | 0.03% |
| Arrowstreet Capital, Limited Partnership | 638,368 | 2.82% | $19.01M | – | 0.01% |
| Geode Capital Management, LLC | 586,334 | 2.59% | $17.47M | +29,540 | 0.00% |
| State Street Corp | 576,134 | 2.54% | $17.16M | +7,708 | 0.00% |
| Next Century Growth Investors LLC | 480,207 | 2.12% | $14.30M | +52,048 | 0.76% |
| Lsv Asset Management | 479,927 | 2.12% | $14.29K | – | 0.03% |
| Renaissance Technologies LLC | 474,100 | 2.09% | $14.12M | −36,797 | 0.02% |
| First Light Asset Management, LLC | 462,562 | 2.04% | $13.78M | New | 0.84% |
| Jupiter Topco LLC | 397,278 | 1.75% | $11.83M | New | 0.00% |
| Pinnacle Associates Ltd | 327,117 | 1.44% | $9.74M | +311 | 0.11% |
| Punch & Associates Investment Management, Inc. | 315,000 | 1.39% | $9.38M | +15,000 | 0.46% |
| Dana Investment Advisors, Inc. | 306,209 | 1.35% | $9.12M | New | 0.24% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 181 | 22M | 96.7% | 29 / 82 | 44 / 30 | 3M | 3M |
| Q1 2026 | 185 | 21M | 94.8% | 41 / 65 | 58 / 21 | 5M | 2M |
| Q4 2025 | 169 | 21M | 91.0% | 51 / 53 | 48 / 8 | 5M | 5M |
| Q3 2025 | 126 | 20M | 89.8% | 17 / 49 | 38 / 17 | 1M | 2M |
| Q2 2025 | 127 | 21M | 92.9% | 14 / 41 | 56 / 27 | 3M | 3M |
| Q1 2025 | 140 | 22M | 96.0% | 22 / 43 | 53 / 21 | 3M | 2M |
| Q4 2024 | 141 | 21M | 93.4% | 37 / 39 | 42 / 25 | 2M | 3M |
| Q3 2024 | 130 | 22M | 97.5% | 26 / 45 | 35 / 27 | 5M | 3M |
| Q2 2024 | 132 | 23M | 99.5% | 22 / 53 | 40 / 28 | 4M | 4M |
| Q1 2024 | 138 | 23M | 100.0% | 29 / 39 | 49 / 23 | 5M | 2M |
| Q4 2023 | 132 | 20M | 88.4% | 22 / 46 | 42 / 45 | 5M | 5M |
| Q3 2023 | 155 | 20M | 89.8% | 33 / 59 | 44 / 28 | 5M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TCMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 686,535 | 3.03% | $20.45M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 598,451 | 2.64% | $17.82M | 0.02% | Jun 30, 2026 |
| Janus Henderson Small Cap Value Fund | 397,237 | 1.75% | $11.83M | 0.93% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 329,945 | 1.46% | $9.29M | 0.41% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 261,835 | 1.16% | $7.80M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 250,114 | 1.10% | $7.05M | 0.02% | Jul 31, 2026 |
| Avantis U.S. Small Cap Value ETF | 240,781 | 1.06% | $5.93M | 0.02% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 190,594 | 0.84% | $5.68M | 0.18% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 179,648 | 0.79% | $5.35M | 0.03% | Jun 30, 2026 |
| U.S. Targeted Value Portfolio | 163,645 | 0.72% | $4.61M | 0.03% | Jul 31, 2026 |
| U.S. Small Cap Value Portfolio | 157,800 | 0.70% | $4.45M | 0.02% | Jul 31, 2026 |
| Dimensional U.S. Targeted Value ETF | 147,758 | 0.65% | $4.16M | 0.03% | Jul 31, 2026 |
| Driehaus Micro Cap Growth Fund | 147,581 | 0.65% | $4.39M | 0.74% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 130,500 | 0.58% | $3.89M | 0.03% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 121,214 | 0.54% | $3.61M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sheri Louise Dodd | Chief Executive Officer, Director | 232,907 | 1.03% | Aug 12, 2026 |
| Elaine M. Birkemeyer | CHIEF FINANCIAL OFFICER | 130,188 | 0.57% | May 13, 2026 |
| Kristie Burns | Sr. VP Mktg & Clinical Affairs | 82,581 | 0.36% | Feb 26, 2026 |
| Raymond Huggenberger | Director | 62,841 | 0.28% | May 8, 2026 |
| Valerie L. Asbury | Director | 55,343 | 0.24% | May 8, 2026 |
| David Brent Shafer | Director | 55,343 | 0.24% | May 8, 2026 |
| Boyd Vindell Washington | Director | 41,768 | 0.18% | May 8, 2026 |
| Laura G. King | Director | 25,569 | 0.11% | May 8, 2026 |
| Andrea Pearson | Director | 7,373 | 0.03% | May 8, 2026 |
| Carmen B. Volkart | Director | 44,219 | 0.20% | May 8, 2026 |
| William W. Burke | Director | 55,041 | 0.24% | May 8, 2026 |
| Daniel L. Reuvers | Director | 214,604 | 0.95% | Mar 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sheri Louise Dodd Chief Executive Officer, Director | Aug 10, 2026 | Sale | −10,978 | $29.44 | $323.19K | 232,907 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | May 11, 2026 | Sale | −4,631 | $24.49 | $113.41K | 130,188 |
| Boyd Vindell Washington Director | May 6, 2026 | Award | +6,521 | – | – | 41,768 |
| Valerie L. Asbury Director | May 6, 2026 | Award | +6,521 | – | – | 55,343 |
| Raymond Huggenberger Director | May 6, 2026 | Award | +6,521 | – | – | 62,841 |
| Laura G. King Director | May 6, 2026 | Award | +6,521 | – | – | 25,569 |
| Carmen B. Volkart Director | May 6, 2026 | Award | +6,521 | – | – | 44,219 |
| William W. Burke Director | May 6, 2026 | Award | +6,521 | – | – | 55,041 |
| David Brent Shafer Director | May 6, 2026 | Award | +6,521 | – | – | 55,343 |
| Andrea Pearson Director | May 6, 2026 | Award | +6,521 | – | – | 7,373 |
| Andrea Pearson Director | Mar 9, 2026 | Award | +852 | – | – | 852 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 24, 2026 | Sale | −10,993 | $28.94 | $318.14K | 243,885 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 24, 2026 | Sale | −7,701 | $28.94 | $222.87K | 134,819 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 24, 2026 | Sale | −6,246 | $28.94 | $180.76K | 82,581 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 23, 2026 | Sale | −160 | $28.69 | $4.59K | 88,827 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 23, 2026 | Sale | −4,279 | $28.28 | $121.01K | 88,987 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 23, 2026 | Sale | −196 | $28.69 | $5.62K | 142,520 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 23, 2026 | Sale | −5,322 | $28.28 | $150.51K | 142,716 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 23, 2026 | Sale | −537 | $28.69 | $15.41K | 254,878 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 23, 2026 | Sale | −14,703 | $28.28 | $415.80K | 255,415 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 20, 2026 | Award | +3,490 | – | – | 82,085 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 20, 2026 | Award | +4,058 | – | – | 86,143 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 20, 2026 | Award | +7,123 | – | – | 93,266 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 20, 2026 | Award | +15,575 | – | – | 148,038 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 20, 2026 | Award | +6,765 | – | – | 132,463 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 20, 2026 | Award | +3,579 | – | – | 125,698 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 20, 2026 | Award | +19,751 | – | – | 241,902 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 20, 2026 | Award | +28,216 | – | – | 270,118 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 19, 2026 | Award | +6,194 | – | – | 78,595 |
| Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER | Feb 19, 2026 | Award | +23,008 | – | – | 122,119 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 19, 2026 | Award | +48,672 | – | – | 222,151 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Jan 2, 2026 | Sale(10b5-1 plan) | −5,139 | $28.85 | $148.26K | 72,401 |
| Sheri Louise Dodd Chief Executive Officer, Director | Aug 8, 2025 | Sale | −7,762 | $12.36 | $95.94K | 173,479 |
| Elaine M. Birkemeyer Chief Financial Officer | May 12, 2025 | Sale(10b5-1 plan) | −2,921 | $9.94 | $29.03K | 99,111 |
| Sheri Louise Dodd Chief Executive Officer, Director | May 8, 2025 | Sale | −3,149 | $9.83 | $30.95K | 181,241 |
| William W. Burke Director | May 8, 2025 | Sale(10b5-1 plan) | −3,300 | $9.67 | $31.91K | 48,520 |
| Boyd Vindell Washington Director | May 7, 2025 | Award | +16,078 | – | – | 35,247 |
| David Brent Shafer Director | May 7, 2025 | Award | +16,078 | – | – | 48,822 |
| Valerie L. Asbury Director | May 7, 2025 | Award | +16,078 | – | – | 48,822 |
| Laura G. King Director | May 7, 2025 | Award | +16,078 | – | – | 19,048 |
| Raymond Huggenberger Director | May 7, 2025 | Award | +16,078 | – | – | 56,320 |
| Carmen B. Volkart Director | May 7, 2025 | Award | +16,078 | – | – | 37,698 |
| William W. Burke Director | May 7, 2025 | Award | +16,078 | – | – | 51,820 |
| Daniel L. Reuvers Director | Mar 11, 2025 | Gift | −68,162 | – | – | 146,442 |
| Daniel L. Reuvers Director | Mar 11, 2025 | Gift | +68,162 | – | – | 68,162 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 25, 2025 | Sale | −6,468 | $14.40 | $93.14K | 77,540 |
| Daniel L. Reuvers Director | Feb 25, 2025 | Sale(10b5-1 plan) | −28,338 | $14.18 | $401.83K | 214,604 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 25, 2025 | Sale(10b5-1 plan) | −2,066 | $14.51 | $29.98K | 102,032 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 24, 2025 | Sale(10b5-1 plan) | −3,778 | $14.70 | $55.54K | 104,098 |
| Daniel L. Reuvers Director | Feb 24, 2025 | Sale(10b5-1 plan) | −10,938 | $14.55 | $159.15K | 242,942 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 24, 2025 | Sale | −4,830 | $14.65 | $70.76K | 84,008 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 20, 2025 | Award | +6,887 | – | – | 71,628 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 20, 2025 | Award | +3,446 | – | – | 64,741 |
| Elaine M. Birkemeyer Chief Financial Officer | Feb 20, 2025 | Award | +36,248 | – | – | 107,876 |
| Laura G. King Director | Feb 20, 2025 | Award | +2,970 | – | – | 2,970 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 20, 2025 | Award | +65,669 | – | – | 184,390 |
| Sheri Louise Dodd Chief Executive Officer, Director | Feb 20, 2025 | Award | +20,108 | – | – | 118,721 |
| Daniel L. Reuvers Director | Feb 20, 2025 | Award | +15,853 | – | – | 253,880 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 20, 2025 | Award | +4,131 | – | – | 72,259 |
| Kristie Burns Sr. VP Mktg & Clinical Affairs | Feb 20, 2025 | Award | +3,359 | – | – | 68,128 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| W. Burke William board of director | Aug 20, 2026 | 15,000 | $540.26M | Aug 19, 2026 | Restricted |
| Sheri Louise Dodd Officer, Director | Aug 10, 2026 | 10,978 | $323.24K | Aug 10, 2026 | Restricted Stock Vesting |
| Elaine M. Birkemeyer Officer | May 11, 2026 | 4,631 | $113.40K | May 11, 2026 | Restricted Stock Vesting |
| Kristie Burns Officer | Feb 25, 2026 | 4,000 | $113.88K | Feb 25, 2026 | Restricted Stock Vesting |
| Sheri Louise Dodd Officer, Director | Feb 24, 2026 | 10,993 | $318.15K | Feb 24, 2026 | Restricted Stock Vesting |
| Elaine M. Birkemeyer Officer | Feb 24, 2026 | 7,701 | $222.87K | Feb 24, 2026 | Restricted Stock Vesting |
| Kristie Burns Officer | Feb 24, 2026 | 6,246 | $180.77K | Feb 24, 2026 | Restricted Stock Vesting |
| Elaine M. Birkemeyer Officer | Feb 23, 2026 | 5,518 | $156.14K | Feb 23, 2026 | Restricted Stock Vesting |
| Kristie Burns Officer | Feb 23, 2026 | 4,439 | $125.61K | Feb 23, 2026 | Restricted Stock Vesting |
| Sheri Louise Dodd Officer, Director | Feb 23, 2026 | 15,240 | $431.25K | Feb 23, 2026 | Restricted Stock Vesting |
| Kristie Burns Officer | Jan 2, 2026 | 5,139 | $148.26K | Jan 2, 2026 | Restricted Stock Vesting |
| Sheri Louise Dodd Officer, Director | Aug 8, 2025 | 7,762 | $95.91K | Aug 8, 2025 | Restricted Stock Vesting |
| Elaine M. Birkemeyer Officer | May 12, 2025 | 2,921 | $29.04K | May 12, 2025 | Vesting of restricted stock unit award |
| Sheri Louise Dodd Director | May 8, 2025 | 3,149 | $30.95K | May 8, 2025 | Vesting of restricted stock unit award |
| William W. Burke Director | May 8, 2025 | 3,300 | $31.91K | May 8, 2025 | Vesting of restricted stock unit award |